Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051043 | 1.00 | MMP2 (0.36) | MMP2MMP3MMP13EPHX2DGAT1 | |
| SCHEMBL1047605 | 1.00 | MMP2 (0.36) | MMP2MMP3MMP13EPHX2DGAT1 | |
| SCHEMBL20054644 | 0.91 | DGAT1 (0.39) | EPHX2DGAT1EPHX1 | |
| SCHEMBL11708952 | 0.85 | EPHX1 (0.38) | EPHX2DGAT1EPHX1CHRM3 | |
| SCHEMBL4956011 | 0.83 | EPHX1 (0.41) | EPHX2DGAT1EPHX1CYP3A4MAPT | |
| SCHEMBL1045346 | 0.82 | EPHX2 (0.35) | EPHX2DGAT1EPHX1MAPTKDM4E | |
| SCHEMBL1045347 | 0.82 | EPHX2 (0.35) | EPHX2DGAT1EPHX1MAPTKDM4E | |
| SCHEMBL15721883 | 0.82 | CHRM2 (0.41) | MMP2MMP3MMP13EPHX2DGAT1 | |
| SCHEMBL21122979 | 0.82 | CHRM2 (0.41) | MMP2MMP3MMP13EPHX2DGAT1 | |
| SCHEMBL15722038 | 0.82 | CHRM2 (0.41) | MMP2MMP3MMP13EPHX2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| EP-1756037-B1 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-7786307-B2 | suchas N-(4(S)-amino-5(S)-hydroxy-2(S)-isopropyl-6-piperidin-1-ylhexyl)-2-(3-methoxypropoxy)benzamide dihydrochloride, used for the treatment of hypertension, cardiovasculr disorders, complications owing to diabetes, vision deffects, hyperaldosteronism, states of anxiety and cognitive disorders | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| US-7767690-B2 | Amino alcohol derivatives and their use as renin inhibitor | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| EP-1735270-B1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-7718675-B2 | Diamino alcohols and their use as renin inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2010-05-18 | — | — | US | disclosed |
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| US-20070161622-A1 | 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-12 | — | — | US | disclosed |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070021399-A1 | Amido-amino alcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-01-25 | — | — | US | disclosed |
| EP-1745777-A1 | Amido-aminoalcohols as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745778-A2 | Diaminoalcohols as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| EP-1735270-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1711456-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005070871-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070870-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070877-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021399-A1 | Amido-amino alcohols as therapeutic compounds | CTSD, BACE1, CTSL | MMP2 232/4885MMP3 644/4885MMP13 2485/4885 |
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | REN, AGTR1, ADH1A | MMP2 1080/4885MMP3 2546/4885MMP13 3598/4885 |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | REN, AGTR1, AGTR2 | MMP2 541/4885MMP3 2307/4885MMP13 3478/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | MMP2 1458/4885MMP3 2506/4885MMP13 3678/4885 |
| US-20070161622-A1 | 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis | REN, AGTR1, AGTR2 | MMP2 545/4885MMP3 478/4885MMP13 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.